Literature DB >> 18574251

Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system.

Joseph Azzarello1, Kar-Ming Fung, Hsueh-Kung Lin.   

Abstract

Human aldo-keto reductase (AKR) 1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase) catalyzes androgen, estrogen, and prostaglandin metabolism. AKR1C3 is therefore implicated in regulating ligand access to the androgen receptor, estrogen receptor, and peroxisome proliferator activating receptor gamma in hormone target tissues. Recent reports on close relationships between ARK1C3 and various cancers including breast and prostate cancers implicate the involvement of AKR1C3 in cancer development or progression. We previously described the characterization of an isoform-specific monoclonal antibody against AKR1C3 that does not cross-react with related, >86% sequence identity, human AKR1C1, AKR1C2, or AKR1C4, human aldehyde reductase AKR1A1, or rat 3alpha-hydroxysteroid dehydrogenase (AKR1C9). In this study, a clone of murine monoclonal antibody raised against AKR1C3 was identified and characterized for its recognition of rat homolog. Tissue distribution of human AKR1C3 and its rat homolog in adult genitourinary systems including kidney, bladder, prostate, and testis was studied by IHC. A strong immunoreactivity was detected not only in classically hormone-associated tissues such as prostate and testis but also in non-hormone-associated tissues such as kidney and bladder in humans and rats. The distribution of these two enzymes was comparable but not identical between the two species. These features warrant future studies of AKR1C3 in both hormone- and non-hormone-associated tissues and identification of the rodent homolog for establishing animal models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574251      PMCID: PMC2516960          DOI: 10.1369/jhc.2008.951384

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  42 in total

1.  A new nomenclature for the aldo-keto reductase superfamily.

Authors:  J M Jez; T G Flynn; T M Penning
Journal:  Biochem Pharmacol       Date:  1997-09-15       Impact factor: 5.858

Review 2.  Comparative anatomy of the aldo-keto reductase superfamily.

Authors:  J M Jez; M J Bennett; B P Schlegel; M Lewis; T M Penning
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

3.  In situ androgen producing enzymes in human prostate cancer.

Authors:  Yasuhiro Nakamura; Takashi Suzuki; Masao Nakabayashi; Mareyuki Endoh; Kazuhiro Sakamoto; Yoshiki Mikami; Takuya Moriya; Akihiro Ito; Shoki Takahashi; Shogo Yamada; Yoichi Arai; Hironobu Sasano
Journal:  Endocr Relat Cancer       Date:  2005-03       Impact factor: 5.678

4.  Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.

Authors:  Hsueh-Kung Lin; Stephan Steckelbroeck; Kar-Ming Fung; Amy N Jones; Trevor M Penning
Journal:  Steroids       Date:  2004-12       Impact factor: 2.668

5.  Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.

Authors:  Dirk O Stichtenoth; Verena Marhauer; Dimitrios Tsikas; Frank-Mathias Gutzki; Jürgen C Frölich
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

6.  Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo.

Authors:  Martin B Oleksiewicz; Inger Thorup; Henriette S Nielsen; Hanne V Andersen; Anne Charlotte Hegelund; Lars Iversen; Torben S Guldberg; Peter R Brinck; Ingrid Sjogren; Ulla K Thinggaard; Lis Jørgensen; Marianne B Jensen
Journal:  Toxicol Pathol       Date:  2005       Impact factor: 1.902

7.  Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity.

Authors:  K Matsuura; H Shiraishi; A Hara; K Sato; Y Deyashiki; M Ninomiya; S Sakai
Journal:  J Biochem       Date:  1998-11       Impact factor: 3.387

8.  Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions.

Authors:  Qing Lan; Judy L Mumford; Min Shen; David M Demarini; Matthew R Bonner; Xingzhou He; Meredith Yeager; Robert Welch; Stephen Chanock; Linwei Tian; Robert S Chapman; Tongzhang Zheng; Phouthone Keohavong; Neil Caporaso; Nathaniel Rothman
Journal:  Carcinogenesis       Date:  2004-07-29       Impact factor: 4.944

9.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

10.  Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase.

Authors:  I Dufort; P Rheault; X F Huang; P Soucy; V Luu-The
Journal:  Endocrinology       Date:  1999-02       Impact factor: 4.736

View more
  18 in total

1.  Effects of genistein and equol on human and rat testicular 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities.

Authors:  Guo-Xin Hu; Bing-Hai Zhao; Yan-Hui Chu; Hong-Yu Zhou; Benson T Akingbemi; Zhi-Qiang Zheng; Ren-Shan Ge
Journal:  Asian J Androl       Date:  2010-05-10       Impact factor: 3.285

2.  Fine mapping analysis confirms and strengthens linkage of four chromosomal regions in familial hypospadias.

Authors:  Cilla Söderhäll; Izabella Baranowska Körberg; Hanh T T Thai; Jia Cao; Yougen Chen; Xufeng Zhang; Zu Shulu; Loes F M van der Zanden; Iris A L M van Rooij; Louise Frisén; Nel Roeleveld; Ellen Markljung; Ingrid Kockum; Agneta Nordenskjöld
Journal:  Eur J Hum Genet       Date:  2014-07-02       Impact factor: 4.246

3.  In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).

Authors:  Aya Kikuchi; Takashi Furutani; Hidenori Azami; Kazushi Watanabe; Tatsuya Niimi; Yoshiteru Kamiyama; Sadao Kuromitsu; Edwina Baskin-Bey; Marten Heeringa; Taoufik Ouatas; Kentaro Enjo
Journal:  Invest New Drugs       Date:  2014-07-01       Impact factor: 3.850

4.  Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues.

Authors:  Charles Dai; Yoon-Mi Chung; Evan Kovac; Ziqi Zhu; Jianneng Li; Cristina Magi-Galluzzi; Andrew J Stephenson; Eric A Klein; Nima Sharifi
Journal:  Clin Cancer Res       Date:  2017-07-21       Impact factor: 12.531

Review 5.  The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.

Authors:  Ian M Bird; David H Abbott
Journal:  J Steroid Biochem Mol Biol       Date:  2016-05-03       Impact factor: 4.292

6.  Differential expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.

Authors:  Aubrey L Park; Hsueh-Kung Lin; Qing Yang; Chor Wing Sing; Michael Fan; Timothy B Mapstone; Naina L Gross; Mary K Gumerlock; Michael D Martin; Craig H Rabb; Kar-Ming Fung
Journal:  Int J Clin Exp Pathol       Date:  2010-03-25

7.  Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.

Authors:  Valerie L Miller; Hsueh-Kung Lin; Paari Murugan; Michael Fan; Trevor M Penning; Lacy S Brame; Qing Yang; Kar-Ming Fung
Journal:  Int J Clin Exp Pathol       Date:  2012-04-26

Review 8.  The Genetic and Environmental Factors Underlying Hypospadias.

Authors:  Aurore Bouty; Katie L Ayers; Andrew Pask; Yves Heloury; Andrew H Sinclair
Journal:  Sex Dev       Date:  2015-11-28       Impact factor: 1.824

9.  Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.

Authors:  Theodore S Chang; Hsueh-Kung Lin; Kyle A Rogers; Lacy S Brame; Matthew M Yeh; Qing Yang; Kar-Ming Fung
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

10.  Bladder cancer SNP panel predicts susceptibility and survival.

Authors:  Angeline S Andrew; Jiang Gui; Arthur C Sanderson; Rebecca A Mason; Elaine V Morlock; Alan R Schned; Karl T Kelsey; Carmen J Marsit; Jason H Moore; Margaret R Karagas
Journal:  Hum Genet       Date:  2009-03-01       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.